Skip to content
Lower risk Drug recall · FDA · Published January 27, 2021

Meitheal Cisatracurium Injection Recall: Label Mix-Up Risk

Meitheal Pharmaceuticals recalls 10-vial Cisatracurium Besylate Injection due to mislabeling with Phenylephrine Hydrochloride. Affected units may contain incorrect medication.

🇺🇸 FDA recall #D-0286-2021DrugMeitheal Pharmaceuticals ›
Take action

Contact the company

Recalling firmMeitheal Pharmaceuticals Inc8700 W Bryn Mawr Ave Ste 600 · Chicago, IL 60631-3512
✎ GovInfoNow plain-language explainer

Meitheal Pharmaceuticals is recalling Cisatracurium Besylate Injection vials that were mislabeled as Phenylephrine Hydrochloride. This could lead to incorrect medication use during medical procedures. The recall affects specific vial packaging with NDC 71288-712-05. Read more at govinfonow.com/recall/36543-meitheal-cisatracurium-injection-recall-label-mix-up-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/36543-meitheal-cisatracurium-injection-recall-label-mix-up-risk · Updated October 4, 2026 · FDA enforcement record: FDA #D-0286-2021

Cite this page

“Meitheal Cisatracurium Injection Recall: Label Mix-Up Risk.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/36543-meitheal-cisatracurium-injection-recall-label-mix-up-risk. Based on FDA recall #D-0286-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0286-2021%22&limit=1).

The FDA announced on Jan. 27, 2021, that Meitheal Pharmaceuticals Inc is recalling Cisatracurium Besylate Injection, USP due to a labeling mix-up where vials were mislabeled as Phenylephrine Hydrochloride Injection, according to the FDA.

How to tell if you have it

  • Brand: Meitheal Pharmaceuticals
  • Product: Cisatracurium Besylate Injection, USP, 10mg per 5mL (2 mg per mL), Single-Dose Vial
  • NDC: 71288-712-05 and 71288-712-06
  • Lot code: C11507A
  • Quantity: 34,860 vials

The hazard

The recall involves a labeling error where cartons of Cisatracurium Besylate Injection contained ten vials mislabeled as Phenylephrine Hydrochloride Injection, according to the FDA. The record states the vials were confirmed to contain Cisatracurium.

Context

GovInfoNow's records show Meitheal Pharmaceuticals, Inc has two other recalls on file since Sept. 3, 2021, including a Feb. 9, 2026 recall for Cetrorelix Acetate Injection Kits with missing or duplicated needles. Other recent recalls of similar products include a Nov. 26, 2025 Somerset Therapeutics Cisatracurium Besylate Injection recall for subpotent product risk and an Aug. 19, 2026 American Health Packaging Buprenorphine Tablets recall for label mix-up hazard.

How to tell if you have this one

Check for vials labeled as 'Phenylephrine Hydrochloride Injection, USP' but containing Cisatracurium Besylate. The product has NDC 71288-712-05 (10 vials per carton) and was manufactured in Chicago, IL.

  • Brand
    Meitheal Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Medication Label

    Verify the label on the vial to ensure it correctly states 'Cisatracurium Besylate Injection, USP' and not 'Phenylephrine Hydrochloride Injection, USP'.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 2.7 years after the firm started it.

1. Firm started the recall: Jan 27, 202112. FDA classified it Class I: Feb 22, 202123. Published in FDA’s Enforcement Report: Mar 3, 202134. FDA terminated the recall: Oct 16, 2023420212023
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0286-2021 (January 27, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0286-2021 to see it in context.
  • Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA